N-Substituted Benzyl Matrinic Acid Derivatives Inhibit Hepatitis C Virus (HCV) Replication through Down-Regulating Host Heat-Stress Cognate 70 (Hsc70) Expression

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Du, Na Na ^a   Peng, Zong Gen ^a   Bi, Chong Wen ^a   Tang, Sheng ^a   Li, Ying Hong ^a   Li, Jian Rui ^a   Zhu, Yan Ping ^a   Zhang, Jing Pu ^a   Wang, Yan Xiang ^a   Jiang, Jian Dong ^a,b   Song, Dan Qing ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

12 N 1 NAPHTHYLMETHYLENYL MATRINIC ACID; 12 N 2 CHLOROBENZYL MATRINIC ACID; 12 N 2 FLUOROBENZYL MATRINIC ACID; 12 N 2 FLUOROBENZYL SOPHORIDINIC ACID; 12 N 2 METHYLBENZYL MATRINIC ACID; 12 N 2,4 DICHLOROBENZYL MATRINIC ACID; 12 N 3 CHLOROBENZYL MATRINIC ACID; 12 N 3 FLUOROBENZYL MATRINIC ACID; 12 N 3 METHYLBENZYL MATRINIC ACID; 12 N 3 METHYLBENZYL SOPHORIDINIC ACID; 12 N 3,4 DICHLOROBENZYL MATRINIC ACID; 12 N 4 BROMOBENZYL MATRINIC ACID; 12 N 4 CHLOROBENZYL MATRINIC ACID; 12 N 4 FLUOROBENZYL MATRINIC ACID; 12 N 4 FLUOROBENZYL SOPHORIDINIC ACID; 12 N 4 METHOXYBENZYL SOPHORIDINIC ACID; 12 N 4 METHYLBENZYL MATRINIC ACID; 12 N 4 METHYLBENZYL SOPHORIDINIC ACID; 12 N 4 TRIFLUOROMETHOXYBENZYL MATRINIC ACID; 12 N 4 TRIFLUOROMETHOXYBENZYL SOPHORIDINIC ACID; 12 N 4 VINYLBENZYL MATRINIC ACID; ANTIVIRUS AGENT; HEAT SHOCK COGNATE PROTEIN 70; N BENZYL MATRINIC ACID DERIVATIVE; N BENZYL SOPHORIDINIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LD 50; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICITY TESTING; VIRUS INHIBITION;

ALKALOIDS; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DOWN-REGULATION; HEPACIVIRUS; HSC70 HEAT-SHOCK PROTEINS; HUMANS; MALE; MICE; MICE, INBRED ICR; QUINOLIZINES; SAFETY; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 84875048598     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058675     Document Type: Article

References (24)

1. Piai G, Scalice E, Focareta R, Terracciano F, de Filippo FR, et al. (2006) From trials to a real hospital setting: effectiveness of pegylated interferon-alpha-2b/ribavirin combination therapy for naïve chronic hepatitis C patients. Dig Dis Sci 51: 1619-1626. (b) Qureshi SA (2007) Hepatitis C virus-biology, host evasion strategies, and promising new therapies on the horizon. Med Res Rev 27: 353-373.
2. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, et al. (2009) Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 361: 580-593.
3. Zeuzem S, (2008) Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat Clin Pract Gastroenterol Hepatol 5: 610-622.
4. Thompson AJ, McHutchison JG, (2009) Review article: investigational agents for chronic hepatitis C. Aliment Pharmacol Ther. 29: 689-705.
5. Pereira AA, Jacobson IM, (2009) New and experimental therapies for HCV. Nat Rev Gastroenterol Hepatol 6: 403-411.
6. Mederacke I, Wedemeyer H, Manns MP, (2009) Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. Curr Opin Investig Drugs 10: 181-189.
7. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, et al. (2009) Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 360: 1839-1850.
8. Thompson AJ, McHutchison JG, (2009) Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J Viral Hepat 16: 377-387.
9. Qiu P, Sanfiorenzo V, Curry S, Guo Z, Liu S, et al. (2009) Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. Nucleic Acids Res 37: e74.
10. Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, et al. (2009) Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50: 1709-1718.
11. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, et al. (2008) Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology 48: 1769-1778.
12. Parent R, Qu X, Petit MA, Beretta L, (2009) The heat shock cognate protein 70 is associated with hepatitis C virus particles and modulates virus infectivity. Hepatology 49: 1798-1809.
13. Peng ZG, Fan B, Du NN, Wang YP, Gao LM, et al. (2010) Small molecular compounds that inhibit hepatitis C virus replication through destabilizing heat shock cognate 70 messenger RNA. Hepatology 52: 845-853.
14. Smith RE, (2006) Hepatitis C virus therapies. Nat Rev Drug Discov 5: 715-716.
15. Soriano V, Peters MG, Zeuzem S, (2009) New therapies for hepatitis C virus infection. Clin Infect Dis 48: 313-320.
16. Gao LM, Han YX, Wang YP, Li YH, Shan YQ, et al. (2011) Design and synthesis of oxymatrine analogues overcoming drug resistance in hepatitis B virus through targeting host heat stress cognate 70. J Med Chem 54: 869-876.
17. Du NN, Li X, Wang YP, Liu F, Liu YX, et al. (2011) Synthesis, structure-activity relationship and biological evaluation of novel N-substituted matrinic acid derivatives as host heat-stress cognate 70 (Hsc70) down-regulators. Bioorg Med Chem Lett 21: 4732-4735.
18. Kamaev FG, Leont'ev VB, Aslanov KA, Ustynyuk YA, Sadykov AS, (1974) NMR investigation of the spatial structure of quinolizidine alkaloids IV. Conformation of sophoridine in solution. Chem Nat Com 10: 765-770.
19. Begisheva AI, Aslanov KA, Sadykov AS, (1968) Spacial structure of sophoridine and sophoridinic acid. Khimiya Prirodnykh Seodinenii 4: 371-372.
20. Ochiai E, Minato H, (1961) Synthesis of matrine derivatives. II. Studies on the diazotization of decarbonylmethylmatrinamine and the ring-closure of matrinic acid derivatives. Chemical and Pharmaceutical Bulletin 9: 92-96.
21. Lv Q, Zhou XL, Wang RX, (2008) Improvements in synthesis of diphenyldi azomethane. Huaxue Shiji. 30: 147.
22. Kelly RC, Schletter I, Stein SJ, Wierenga W, (1979) Total synthesis of α-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125), an antitumor antibiotic. J Am Chem Soc 101: 1054-1056.
23. Nagano N, Satoh M, Hara R, (1991) Studies on beta-lactam antibiotics III. Syntheses and antibacterial activities of new 3-(1,3-dithiolan-2-yl) cephalosporins, YM-22508, YM-16457 and their prodrug-type esters. J Antibiot 44: 422-428.
24. Brown HC, Heim P, (1973) Selective reductions. XVIII. Fast reaction of primary, secondary, and tertiary amides with diborane. Simple, convenient procedure for the conversion of amides to the corresponding amines. J Org Chem 38: 912-916.